Kisqali, a breast cancer pill made by Novartis, reduced the risk of recurrence of the most common type of early breast cancer by 25% in a key trial, researchers said Friday.
The findings will likely lead to regulatory approvals and broader use of the medicine, which could represent a financial windfall for Novartis. The company has forecast that the new market for the medicine could reach $3 billion. That could set up a marketing battle with Eli Lilly, which makes a similar product called Verzenio, as well as a continuing loss of share for Pfizer’s Ibrance.
“It’s good news in the sense that this is the most common type of breast cancer,” said Harold Burstein, a breast cancer oncologist at the Dana-Farber Cancer Center.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect